A lengthy R&D update for CytomX’s pipeline review day included a brief note on a housecleaning at Bristol-Myers Squibb that cost the smaller biotech a partner on 3 of their allied programs.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.Free Subscription